Surface Protein gp120 - Pipeline Review, H2 2016

  • ID: 3895097
  • Report
  • 75 pages
  • Global Markets Direct
1 of 6

FEATURED COMPANIES

  • GlaxoSmithKline Plc
  • Osel, Inc.
  • Sanofi Pasteur SA
  • TeneoBio Inc
  • United Biomedical, Inc.
  • ViiV Healthcare Limited
  • MORE
Surface Protein gp120 - Pipeline Review, H2 2016

Summary

‘Surface Protein gp120 - Pipeline Review, H2 2016’, provides in depth analysis on Surface Protein gp120 targeted pipeline therapeutics.

The report provides comprehensive information on the Surface Protein gp120, targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Surface Protein gp120 targeted therapeutics development and features dormant and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
*Updated report will be delivered in 48 hours of order confirmation.

Scope

- The report provides a snapshot of the global therapeutic landscape for Surface Protein gp120
- The report reviews Surface Protein gp120 targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Surface Protein gp120 targeted therapeutics and enlists all their major and minor projects
- The report assesses Surface Protein gp120 targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Surface Protein gp120 targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Surface Protein gp120
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Surface Protein gp120 development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 6

FEATURED COMPANIES

  • GlaxoSmithKline Plc
  • Osel, Inc.
  • Sanofi Pasteur SA
  • TeneoBio Inc
  • United Biomedical, Inc.
  • ViiV Healthcare Limited
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Surface Protein gp120 Overview

Therapeutics Development

Surface Protein gp120 - Products under Development by Stage of Development

Surface Protein gp120 - Products under Development by Therapy Area

Surface Protein gp120 - Products under Development by Indication

Surface Protein gp120 - Pipeline Products Glance

Late Stage Products

Early Stage Products

Surface Protein gp120 - Products under Development by Companies

Surface Protein gp120 - Products under Development by Universities/Institutes

Surface Protein gp120 - Therapeutics Assessment

Assessment by Monotherapy/Combination Products

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Surface Protein gp120 - Companies Involved in Therapeutics Development

GlaxoSmithKline Plc

Osel, Inc.

Sanofi Pasteur SA

TeneoBio Inc

United Biomedical, Inc.

ViiV Healthcare Limited

Surface Protein gp120 - Drug Profiles

Abzentek - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AIDSVAX B/B + ALVAC-HIV vCP1521 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Biologic for Infectious Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BMD-101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BMD-104 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BMS-585248 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DS-003 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

fostemsavir tromethamine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HIV [strains C1086 + TV1] (bivalent) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HIV vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HIV vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HIV vaccine 1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HIV-1 vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HNG-156 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

M-48U1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibodies to Inhibit GP120 for HIV - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibodies to Inhibit Gp120 for HIV-1 Infection - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibodies to Target GP120 and GP41 for HIV - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Inhibit Glycoprotein 120 for HIV - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Peptide to Inhibit gp120 for HIV-1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Protein to Target gp120 for HIV-1 Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Target GP120 and Gp41 for HIV-1 Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptides to Inhibit GP120, GP41, Tat, Integrase and Protease for HIV-1 Infection - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VCP-2438 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VRC-01LS - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Surface Protein gp120 - Dormant Projects

Surface Protein gp120 - Discontinued Products

Surface Protein gp120 - Featured News & Press Releases

May 18, 2016: Large-scale HIV vaccine trial to launch in South Africa

Jan 07, 2016: National Institutes of Health Initiates Phase 1 Trial of VRC01LS Anti-HIV Therapeutic Antibody Using Xencor's Xtend Fc Technology

Dec 02, 2015: Abzyme Research Foundation's Inaugural ENDHIV BALL Launches $3 Million Fund for New Therapeutic HIV Vaccine Trial

Jul 21, 2015: Bristol-Myers Squibb Receives U.S. FDA Breakthrough Therapy Designation for Investigational HIV-1 Attachment Inhibitor for Heavily Treatment-Experienced Patients

Jul 08, 2015: Scripps research-designed drug candidate significantly reduces HIV reactivation rate

Feb 25, 2015: 48-Week Analysis of Investigational HIV-1 Attachment Inhibitor Paves Way for Phase III Trial Initiation

Oct 03, 2014: Bristol-Myers Squibb Presents Data of BMS-663068 at IDWeek 2014 Showcasing Continued Innovation in Virology

Jul 30, 2014: Dissolvable fabric loaded with medicine might offer faster protection against HIV

Mar 05, 2014: Bristol-Myers Squibb Presents Promising Phase IIb Data for Novel, Investigational Attachment Inhibitor for HIV-1 Infected Treatment-Experienced Patients

May 06, 2013: Duke Researchers Report Additional Information From Phase III HIV Vaccine Trial In Thailand

Dec 06, 2012: Vaginal microbicide gel may offer a promising strategy for prevention and protection against HIV transmission

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Number of Products under Development for, H2 2016

Number of Products under Development by Therapy Area, H2 2016

Number of Products under Development by Indication, H2 2016

Comparative Analysis by Late Stage Development, H2 2016

Comparative Analysis by Early Stage Products, H2 2016

Number of Products under Development by Companies, H2 2016

Products under Development by Companies, H2 2016

Number of Products under Investigation by Universities/Institutes, H2 2016

Products under Investigation by Universities/Institutes, H2 2016

Assessment by Monotherapy/Combination Products, H2 2016

Number of Products by Stage and Mechanism of Action, H2 2016

Number of Products by Stage and Route of Administration, H2 2016

Number of Products by Stage and Molecule Type, H2 2016

Pipeline by GlaxoSmithKline Plc, H2 2016

Pipeline by Osel, Inc., H2 2016

Pipeline by Sanofi Pasteur SA, H2 2016

Pipeline by TeneoBio Inc, H2 2016

Pipeline by United Biomedical, Inc., H2 2016

Pipeline by ViiV Healthcare Limited, H2 2016

Dormant Projects, H2 2016

Dormant Projects (Contd..1), H2 2016

Dormant Projects (Contd..2), H2 2016

Discontinued Products, H2 2016 62List of Figures

Number of Products under Development for, H2 2016

Number of Products under Development by Indication, H2 2016

Comparative Analysis by Late Stage Development, H2 2016

Comparative Analysis by Early Stage Products, H2 2016

Assessment by Monotherapy/Combination Products, H2 2016

Number of Products by Stage and Mechanism of Actions, H2 2016

Number of Products by Routes of Administration, H2 2016

Number of Products by Stage and Routes of Administration, H2 2016

Number of Products by Molecule Types, H2 2016

Number of Products by Stage and Molecule Type, H2 2016
Note: Product cover images may vary from those shown
3 of 6

Loading
LOADING...

4 of 6

FEATURED COMPANIES

  • GlaxoSmithKline Plc
  • Osel, Inc.
  • Sanofi Pasteur SA
  • TeneoBio Inc
  • United Biomedical, Inc.
  • ViiV Healthcare Limited
  • MORE
According to our recently published report 'Surface Protein gp120 – Pipeline Review, H2 2016'; Surface Protein gp120 pipeline Target constitutes close to 25 molecules. Out of which approximately 12 molecules are developed by Companies and remaining by the Universities/Institutes.

Furthermore, the publisher says; Surface Protein gp120 Envelope glycoprotein GP120 is a glycoprotein exposed on the surface of the HIV envelope. The entry of human immunodeficiency virus (HIV) into cells requires the sequential interaction of the viral exterior envelope glycoprotein, gp120, with the CD4 glycoprotein and a chemokine receptor on the cell surface. These interactions initiate a fusion of the viral and cellular membranes.

The report 'Surface Protein gp120 – Pipeline Review, H2 2016' outlays comprehensive information on the Surface Protein gp120 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Surface Protein gp120 targeted therapeutics development, features dormant and discontinued projects and latest news and press releases. Currently, The molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 1, 4 and 4 respectively. Similarly, the Universities portfolio in Phase III, Phase I, Preclinical and Discovery stages comprises 1, 4, 4 and 4 molecules, respectively.
Note: Product cover images may vary from those shown
5 of 6
GlaxoSmithKline Plc
Osel, Inc.
Sanofi Pasteur SA
TeneoBio Inc
United Biomedical, Inc.
ViiV Healthcare Limited
Note: Product cover images may vary from those shown
6 of 6
Note: Product cover images may vary from those shown
Adroll
adroll